AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 52 min read$GEHC

GE HealthCare Adds SOFIE Biosciences In $945M Radiopharma Deal

GE HealthCare (GEHC) agreed to acquire SOFIE Biosciences for $945M in cash, expanding its U.S. radiopharmaceutical market presence. The deal, expected to close in H1 2027, will add 15 manufacturing sites and 21 cyclotrons. GEHC anticipates revenue growth and EPS accretion in the first full year. GEHC shares closed at $64.29, up 0.48%, and were up 0.96% in premarket trading.

Original reporting
rttnews.com
Published Oct 5, 2026, 1:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 1:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The acquisition is expected to be revenue‑accretive and may improve GEHC's earnings per share in the first full year.

02

Market read

A large, cash M&A deal that could boost GEHC's growth outlook and influence the radiopharma sector.

03

What to watch

Regulatory approval timelines and potential competition in the PET market.

Relevance 9/10Novelty 9/10Timing: premarket today

Background

GE HealthCare seeks to expand its final‑mile PET radiopharmaceutical footprint in the U.S.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a $945M cash acquisition of SOFIE Biosciences, a new primary disclosure of a large-scale M&A deal.

Expected impact

upward pressure as the market prices in the accretive acquisition.

Evidence & confidence

Deal size and strategic fit in the radiopharma supply chain suggest investors will view the news favorably.

Market effects

Sector

Strengthens GE HealthCare's position in the radiopharmaceutical and theranostics sector.

Regional

Adds U.S. manufacturing capacity, may boost related biotech and imaging stocks.

Global

Highlights growing U.S. demand for PET radiopharmaceuticals, relevant to global healthcare investors.

Counterpoint

What could challenge this read

If integration costs exceed expectations, the deal could pressure margins.

Key entities

  • Company
    GE HealthCare Technologies Inc.

    Acquirer, US‑listed medical technology firm.

  • Company
    SOFIE Biosciences

    Target, U.S. contract manufacturing organization for PET radiopharmaceuticals.

Read at source← All news

StoryGE HealthCare agrees $945 million purchase of SOFIE Biosciences

Also covered by

6 outlets

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min